← Product Code [MSV](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MSV) · K040451 # VARELISA B2 GLYCOPROTEIN I IGM ANTIBODIES, MODELS 18848 AND 18896 (K040451) _Pharmacia Deutschland GmbH · MSV · May 11, 2004 · Immunology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MSV/K040451 ## Device Facts - **Applicant:** Pharmacia Deutschland GmbH - **Product Code:** [MSV](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MSV.md) - **Decision Date:** May 11, 2004 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.5660 - **Device Class:** Class 2 - **Review Panel:** Immunology ## Indications for Use The Varelisa B2-Glycoprotein I IgM Antibodies Kit is designed for the semiquantitative and qualitative determination of β2-glycoprotein I IgM antibodies in serum or plasma. The presence of β2-glycoprotein I antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of thrombotic disorders related to the primary Antiphospholipid Syndrome or occurring secondary to systemic lupus erythematosis (SLE) or other autoimmune diseases. Prescription use only. ## Device Story Varelisa B2-Glycoprotein I IgM Antibodies is an indirect noncompetitive enzyme immunoassay (EIA) for detecting IgM antibodies against B2-glycoprotein I in human serum or plasma. The test utilizes microplate strips coated with purified human B2-glycoprotein I antigen. Patient samples are incubated; specific antibodies bind to the antigen. An enzyme-labeled conjugate is added, binding to the antigen-antibody complex. A substrate is introduced, producing a color change proportional to the concentration of bound antibodies. The assay is performed in a laboratory setting by trained personnel. Results are interpreted by healthcare providers alongside clinical findings and other laboratory tests to aid in diagnosing thrombotic disorders associated with Antiphospholipid Syndrome or autoimmune conditions like SLE. The device provides a diagnostic aid, potentially improving clinical management of thrombotic risks. ## Clinical Evidence No clinical studies were performed. Analytical performance was established via bench testing, including precision (total CV < 15%), linearity, and interference testing (bilirubin, hemoglobin, chyle, rheumatoid factor). A method comparison study using 42 patient samples (SLE, lupus-like, AIDS, APS, healthy) demonstrated 90.5% qualitative agreement with the predicate device. Reference ranges were established using 432 healthy donors. ## Technological Characteristics Indirect noncompetitive enzyme immunoassay (EIA). Components: microplate strips coated with human purified B2-glycoprotein I antigen, calibrators, controls, enzyme-labeled conjugate, substrate, stop solution, buffered diluent, and wash buffer. Analyte: B2-glycoprotein I IgM antibodies. Sample types: serum and plasma. Evaluation: OD-cutoff based. ## Regulatory Identification A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies). ## Predicate Devices - INOVA QUANTA Lite™ ß2 GPI IgM ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE ONLY TEMPLATE A. 510(k) Number: k040451 B. Purpose of Submission: New device C. Analyte: $\beta 2$-Glycoprotein I IgM antibodies D. Type of Test: Semiquantitative and qualitative ELISA E. Applicant: Pharmacia Deutschland GmbH/Sweden Diagnostics (Germany) GmbH F. Proprietary and Established Names: Varelisa B2-Glycoprotein I IgM Antibodies EIA Kit G. Regulatory Information: 1. Regulation section: 21 CFR 866.5660, Multiple Autoantibodies Immunological Test System 2. Classification: Class II 3. Product Code: MSV, System, Test, Antibodies, $\beta 2$-Glycoprotein I ($\beta 2$-GPI) 4. Panel: Immunology (82) H. Intended Use: 1. Intended use(s): The Varelisa B2-Glycoprotein I IgM Antibodies Kit is designed for the semiquantitative and qualitative determination of $\beta 2$-glycoprotein I IgM antibodies in serum or plasma. 2. Indication(s) for use: The presence of $\beta 2$-glycoprotein I antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of thrombotic disorders related to the primary Antiphospholipid Syndrome or occurring secondary to systemic lupus erythematosis (SLE) or other autoimmune diseases. 3. Special condition for use statement(s): Prescription use only. {1} Page 2 of 6 4. Special instrument Requirements: None. I. Device Description: The Varelisa B2-Glycoprotein I IgM Antibodies kit consists of an ELISA strip wells (12 strips X 8 wells) coated with purified human β2-glycoprotein I antigen. It also contains ancillary reagents such as calibrators, positive and negative controls, wash buffer, sample diluent, antibody-chromogen conjugate, enzyme substrate, stop solution for enzyme reaction, and a frame to hold ELISA strip wells. Also included are a package insert and a control certificate. J. Substantial Equivalence Information: 1. Predicate device name(s): INOVA QUANTA Lite B2 GPI IgM 2. Predicate K number(s): k973014 3. Comparison with predicate: | Similarities | | | | --- | --- | --- | | Item | Device | Predicate | | Intended Use | Semiquantitative and qualitative determination of β2-glycoprotein I IgM antibodies in serum or plasma for use in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of thrombotic disorders related to primary Antiphospholipid Syndrome or occurring secondary to systemic lupus erythematosis (SLE) or other autoimmune diseases. | Qualitative detection of β2-GPI IgM antibodies in serum for use in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of certain autoimmune disease thrombotic disorders, such as those secondary to systemic lupus erythematosis (SLE) or other lupus-like thrombotic diseases. | | Antigen | Human affinity-purified β2-glycoprotein I | β2-glycoprotein I, unknown source | | Conjugate | Anti-human IgM Antibody Conjugate, Horseradish peroxidase | Same | | Assay Principle | Indirect noncompetitive enzyme immunoassay | Same | | Sample dilution | 1:101 | Same | {2} Page 3 of 6 | Differences | | | | --- | --- | --- | | Item | Device | Predicate | | Specimen | Serum and plasma | Serum | | Calibrators | Six prediluted calibrators | Five prediluted calibrators | | Assay evaluation | OD cut-off | Decision point | ## K. Standard/Guidance Document Referenced (if applicable): None ## L. Test Principle: The Varelisa B2-Glycoprotein I IgM Antibodies EIA Kit is an indirect noncompetitive enzyme immunoassay. The wells of the microplate are coated with human purified $\beta 2$-glycoprotein I antigen. Antibodies specific for $\beta 2$-glycoprotein I present in the applied patient sample bind to the antigen and are detected by an enzyme labeled secondary antibody complex, which leads to the formation of an enzyme labeled conjugate-antibody-antigen complex. The enzyme labeled antigen-antibody complex converts the added substrate to form a colored solution. The rate of color formation from the chromogen (substrate) is a function of the amount of conjugate complexed with the bound antibody and thus is proportional to the initial concentration of the respective antibodies in the patient sample. The antibody concentration is determined by comparison to a calibration curve run with the assay and is reported in U/mL. ## M. Performance Characteristics (if/when applicable): ### 1. Analytical performance: #### a. Precision/Reproducibility: Five serum samples (low, medium, high, equivocal, negative) were selected from a serum bank. The samples were diluted 1:101 and measured in 5 runs, with 4 replicates per run. Standards and controls were analyzed in triplicate. Specified target values were: variance "within" < 12%; "between" < 10%; "total" < 15%. The specifications were met for each sample, with the following variances: | Sample ID | | Run 1 | Run 2 | Run 3 | Run 4 | Run 5 | Mean (U/mL) | Variance | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | Within | Between | total | | ZSB 7483 | Mean (u/mL) CV% | 53.0 5.11 | 55.8 2.89 | 54.2 0.85 | 52.4 7.16 | 52.5 2.60 | 53.6 | 4.26 | 1.61 | 4.56 | | ZSB 7170 | Mean (u/mL) CV% | 34.4 0.74 | 35.2 3.82 | 32.3 1.62 | 32.7 4.87 | 29.6 2.25 | 32.8 | 3.08 | 6.42 | 7.12 | | ZSB 6910 | Mean (u/mL) CV% | 16.7 2.31 | 17.3 1.93 | 16.4 3.13 | 16.8 2.78 | 16.2 1.10 | 16.7 | 2.36 | 2.23 | 3.25 | | negative | Mean (u/mL) CV% | 5.3 11.4 | 3.6 1.4 | 3.6 4.7 | 3.5 19.3 | 3.3 7.9 | 3.9 | 11.0 | 19.6 | 22.5 | | equiv. | Mean (u/mL) | 16.7 | 17.3 | 16.4 | 16.8 | 16.2 | 16.7 | 2.4 | 2.2 | 3.3 | {3} Page 4 of 6 | | CV% | 2.31 | 1.93 | 3.13 | 2.78 | 1.10 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | b. Linearity/assay reportable range: Three samples selected from a serum bank were diluted 1:1, 2:3, 1:2, 1:4, 1:8, 1:16, and 1:32 in Sample Diluent. Standards, Controls and each dilution were measured in triplicate. Specifications were that observed/expected units ratio would not differ by more than ± 20% for at least 3 successive dilutions of each tested sample. The dilutions met the criteria and were considered linear, although some of the higher dilutions were >20% over expected. Recovery of analyte was assayed using two samples from a serum bank. Each sample was tested to determine pre-existing antibodies. Each sample was then diluted 1:101 and spiked with 1/10 volume of Standards S1 to S6 and measured in duplicate. Acceptance criteria were that recovery would be 100 ± 20%. In all cases for both samples, the acceptance criteria were met. c. Traceability (controls, calibrators, or method): Not traceable to external sources. The consistency of the calibration material is given by a testing procedure comprising several internal target values that must be met. Each new production of calibration material is adapted to the corresponding master calibration material. d. Detection limit: Sample Buffer was diluted according to Directions for Use and measured 56 times on one plate. Standards and Controls were analyzed in four replicates. Two dilutions of the first standard point, S2 (1:2, 1:4) were run in four replicates. Analytical sensitivity was calculated as the mean of the optical densities of the sample buffer plus 3SD and expressed in U/mL. The discrimination value D, proves the ability to discriminate between the lowest standard point and the background, was performed as follows: $$ D = \frac {\eta_ {B} - \eta_ {A}}{\sqrt {\left(\sigma_ {B} ^ {2} - \sigma_ {A} ^ {2}\right)}} $$ Where: A is Sample Buffer; B is Standard S2; ηA, ηB are mean OD's; σA, σB are SD's. Specifications were that analytical sensitivity should be below 1 U/mL, the mean + 3SD of sample buffer should be < standard point S2, and the discrimination value should be > 2.0. The mean +3SD was 0.021 OD, which corresponded to analytical sensitivity of 0.07 U/mL. The other criteria were met. e. Analytical specificity: Interference was tested against potentially interfering substances found in blood: bilirubin, hemoglobin, chyle, and rheumatoid factor. {4} Page 5 of 6 Three samples from a serum bank were diluted 1:101. Samples were spiked with different super-normal amounts of interferent. Spiked samples were analyzed in triplicate. Acceptance criteria were that spiked samples should show no more than 20% variation from unspiked sample. | Additives (final sample concentration) | I | II | III | IV | V | | --- | --- | --- | --- | --- | --- | | Bilirubin F (mg/dL) | 0.0 | 4.8 | 9.5 | 14.3 | 19.0 | | Bilirubin C (mg/dL) | 0.0 | 5.5 | 11.0 | 16.5 | 22.0 | | Chyle (Units) | 0.0 | 357.5 | 715.0 | 1072.5 | 1430.0 | | Hemoglobin (mg/dL) | 0.0 | 122.5 | 245.0 | 367.5 | 490.0 | | RF (IU/mL) | 0.0 | 98.0 | 294.0 | 490.0 | - | All samples met acceptance criteria and showed no significant influence on the test results. Additional interference tests on negative and equivocal sera with the same interferents demonstrated a negligible effect of the interferents on the negative samples, and a more pronounced effect on the equivocal samples. The negative samples, however, remained negative, so the interference was judged to be not important. f. Assay cut-off: The semi-quantitative cut-points were determined by measuring 432 samples from apparently healthy Caucasian donors, equally distributed by sex and age. Diluted samples, standards, and controls were analyzed in duplicate. Specifications called for the mean +2SD to be smaller than the lower limit of the equivocal range, and the mean +3SD to be smaller than the upper limit of the equivocal range. The following values were selected for negative, equivocal, and positive: <10 U/mL = negative 10-15 U/mL = equivocal >15 U/mL = positive The specifications were fulfilled and no difference was detected between sexes or ages. 2. Comparison studies: a. Method comparison with predicate device: The following samples were used in comparing the new device with 42 samples from a serum bank at Pharmacia, representing SLE, lupus-like, AIDS, APS, unknown clinical diagnosis, and healthy individuals. The results were compared semiquantitatively (Varelisa) {5} Page 6 of 6 vs qualitatively (QUANTA Lite) in a 6 field analysis. 38 of 42 sera agreed qualitatively (pos/neg) for overall agreement of 90.5%. No sera were equivocal or positive by the Varelisa assay and negative by the predicate. Four sera were negative by Varelisa assay and positive by the qualitative predicate. | Varelisa B2-glycoprotein I IgM | n = 42 | INOVA QUANTA Lite | | | --- | --- | --- | --- | | | | Positive | Negative | | Antibodies Assay | positive | 25 | 0 | | | equivocal | 0 | 0 | | | negative | 4 | 13 | b. Matrix comparison: Twenty blood donor samples in the positive and negative range of the assay were tested in serum, citrate plasma, heparin plasma, and EDTA plasma, in the negative range of the assay. No significant differences were noted for any of the matrices. 3. Clinical studies: a. Clinical sensitivity: Not applicable b. Clinical specificity: Not applicable c. Other clinical supportive data (when a and b are not applicable): Not applicable 4. Clinical cut-off: Not applicable 5. Expected values/Reference range: Expected value for normal healthy individuals is negative, or <10 U/mL. In a study of 432 healthy Caucasians, the following values were obtained: N: 432 Mean: 1.1 U/mL Mean +2SD 5.6 U/mL Median: 0.6 U/mL 95th percentile 3.4 U/mL N. Conclusion: The submitted information in this premarket notification is complete, and supports a substantial equivalence decision. --- **Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MSV/K040451](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/MSV/K040451) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com